Myhep All

What the Active Compounds Do

Two direct-acting antiviral agents work together to shut down hepatitis C virus replication at the molecular level. The first compound, sofosbuvir, works by blocking the nonstructural protein 5B polymerase enzyme. The enzyme the hepatitis C virus uses to copy its genetic material inside liver cells. Without that enzyme functioning, the virus cannot replicate. The second compound, velpatasvir, targets a different site entirely. It blocks the nonstructural protein 5A replication complex, which the virus depends on for assembling new viral proteins. Blocking both targets at once leaves the virus with no backup pathway.

Product Identity

Myhep All Tablet contains sofosbuvir 400mg and velpatasvir 100mg in a single fixed-dose combination tablet. It is manufactured by Mylan, a name well established in the generic antiviral supply chain. Each tablet delivers the full dual-mechanism action described above in one unit. Buyers sourcing Myhep All Tablet for reseller or stockist inventory will find this a clean, well-documented product.

Condition This Product Covers

This product is used for the treatment of chronic hepatitis C virus infection across all major genotypes such as: genotype 1 through genotype 6. The fixed-dose combination covers both genotypic breadth and treatment simplicity in a single tablet format. Demand in this treatment category remains steady because the global prevalence of chronic hepatitis C infection continues to be significant. It treats all six genotypes. That breadth is a major commercial driver.

Available Strengths and Pack Sizes

The fixed-dose combination is available in one defined strength: sofosbuvir 400mg with velpatasvir 100mg per tablet. Pack sizes commonly available for bulk order include strips formatted for standard supply cycles. Buyers placing a Myhep All Tablet bulk order should confirm current pack configurations at the time of ordering, as available pack sizes may reflect regional supply formats. The strength per tablet remains consistent across supply. One strength. One compound ratio.

Side Effect

The side effect of the sofosbuvir 400mg and velpatasvir 100mg combination is generally well tolerated across the treatment population. Known effects associated with this compound pairing include fatigue, headache, nausea, and insomnia. These are typical of direct-acting antiviral combinations in this drug category. Heart rhythm changes have been noted in cases where this product is used alongside amiodarone.

This is a documented product interaction relevant to buyers advising downstream distribution. Bradycardia-type effects are the specific concern in that combination. The overall tolerability profile supports steady market demand.

Shelf Life and Storage

Myhep All Tablet should be stored at controlled room temperature, generally between 15 degrees Celsius and 30 degrees Celsius. Humidity exposure should be kept low, and the product should remain in its original blister or strip packaging until point of use. For stockists managing warehouse inventory, standard dry-storage pharmaceutical conditions apply. Shelf life under correct storage conditions is typically 24 months from the manufacturing date, though buyers should verify batch-specific expiry at the point of ordering. Proper storage protects strip integrity. That matters for bulk reseller operations.

Pricing and Availability

GetHIV Treatment carries Myhep All Tablet with pricing structured to support reseller and stockist margins. Buyers comparing Myhep All Tablet price per strip will find the rates here competitive for volume-based ordering. Pricing is available on request for bulk quantities, and the product is listed for international supply where applicable regulations permit online pharmaceutical ordering. Single-unit and multi-unit options are both accessible through the product listing. Volume drives the value here.

Why Buyers Stock This Product

Mylan has a documented track record in producing generic direct-acting antivirals that meet international quality benchmarks. The sofosbuvir and velpatasvir combination in this format has consistent demand because it covers all hepatitis C genotypes without the need for ribavirin in most treatment populations.

A point that matters to buyers evaluating market fit. Resellers and stockists looking for a Myhep All Tablet supplier benefit from the manufacturer’s established regulatory clearances and the product’s broad treatment applicability. Reorder rates in this category are reliable. The combination of genotype coverage, tolerability profile, and manufacturer credentials makes this a practical product for any wholesale buyer operating in the hepatitis C antiviral segment. Bulk order options are available and inquiry response is direct.